CinCor Pharma to Present at Upcoming Jefferies London Healthcare Conference
|Location:||Track 2 – Room, Adelphi 2, Ground Level at the
The CinCor management team will participate in one-on-one investor meetings during the event. Investors interested in meeting with CinCor at the conference should contact their Jefferies representative.
CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, baxdrostat, a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.
|EVP and CFO||ir@CinCor.com|
Source: CinCor Pharma, Inc.